AR and cancer: Early clinical trials targeting the androgen receptor, estrogen receptor, and BTK (Bruton tyrosine kinase) have demonstrated encouraging efficacy and safety profiles, highlighting the potential of protein degraders as a new class of cancer therapeutics [143,144].